₹5,919.00 82.00 (1.40%)
As on October 12, 2026
AstraZeneca Pharma India Limited operates as a biopharmaceutical entity, engaged in the development, production, and global commercialization of pharmaceutical products, serving both the Indian domestic market and international clientele. The company offers an extensive range of medications, including treatments for cardiovascular conditions and diabetes, marketed under brands such as Brilinta, Betaloc, Crestor, Forxiga, Imdur, Kombiglyze XR, Onglyza, Seloken XL, Xigduo XR, and QTERN. Its respiratory portfolio features products like Symbicort and FASENRA, while its oncology division provides various cancer therapies, including LYNPARZA, Tagrisso, Iressa, Calquence, Casodex, Faslodex, Zoladex, and Arimidex. Furthermore, the firm extends its product line to encompass therapeutic solutions for renal, metabolic, and immunological disorders. Beyond its pharmaceutical offerings, AstraZeneca Pharma India Limited also provides clinical trial services. Established in 1979, the company is based in Bengaluru, India, and functions as a subsidiary of AstraZeneca Pharmaceuticals AB.
Total Revenue (YTD)
₹22.8KCAGR 5-Year
+29.64%Sun Pharmaceutical Industries Ltd
Market cap: ₹4,41,477.63 Cr
Divi's Laboratories Ltd
Market cap: ₹2,41,576.41 Cr
Torrent Pharmaceuticals Ltd
Market cap: ₹1,82,576.57 Cr
Missed the last rally? Don’t miss the next
Our AI-powered Analytical Portal finds the strongest technical positive stocks with actionable Buy & Sell opportunities.